These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 38041556

  • 21. Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.
    Hoy SM.
    Am J Clin Dermatol; 2022 May; 23(3):409-420. PubMed ID: 35503162
    [Abstract] [Full Text] [Related]

  • 22. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
    Rosmarin D, Casillas M, Chen S, Dawson Z, Pierce E, Zhang H, Bukhalo M, Smith S.
    J Cutan Med Surg; 2022 May; 26(3):262-266. PubMed ID: 35086348
    [Abstract] [Full Text] [Related]

  • 23. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
    Silverberg JI, Simpson EL, Thyssen JP, Werfel T, Cardillo TE, Colvin S, Pierce E, Chen YF, Chen S, Eichenfield L.
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1036-1045. PubMed ID: 36514996
    [Abstract] [Full Text] [Related]

  • 24. Real-world experience of baricitinib in atopic dermatitis: including add-on therapy for patients using dupilumab.
    Lim JH, Kwon SH, Lew BL.
    Int J Dermatol; 2024 Feb; 63(2):196-200. PubMed ID: 38058206
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
    Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD, Kim MB, Kabashima K, Chen Z, Lu Y, Bansal A, Rossi AB, Shabbir A.
    JAMA Dermatol; 2023 Mar 01; 159(3):255-266. PubMed ID: 36723913
    [Abstract] [Full Text] [Related]

  • 26. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
    Rosmarin D, Fretzin S, Strowd L, Casillas M, DeLozier AM, Dawson Z, Chen S, Lu N, Thyssen JP.
    J Cutan Med Surg; 2022 Mar 01; 26(4):377-385. PubMed ID: 35354410
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
    Silverberg JI, Boguniewicz M, Waibel J, Weisman J, Strowd L, Sun L, Ding Y, Feely M, Nunes FP, Simpson EL.
    Dermatol Ther (Heidelb); 2022 Jan 01; 12(1):137-148. PubMed ID: 34846636
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan.
    Hagino T, Saeki H, Fujimoto E, Kanda N.
    J Dermatol; 2023 Jul 01; 50(7):869-879. PubMed ID: 36890685
    [Abstract] [Full Text] [Related]

  • 30. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
    Hagino T, Hamada R, Yoshida M, Saeki H, Fujimoto E, Kanda N.
    Clin Drug Investig; 2024 Apr 01; 44(4):261-269. PubMed ID: 38446396
    [Abstract] [Full Text] [Related]

  • 31. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
    Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Peñas P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M.
    Dermatol Ther (Heidelb); 2021 Jun 01; 11(3):971-982. PubMed ID: 33899152
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL.
    Am J Clin Dermatol; 2021 May 01; 22(3):395-405. PubMed ID: 33826132
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16.
    Thyssen JP, de Bruin-Weller M, Costanzo A, Grond S, Schuster C, Liu C, Rueda MJ, Chen YF, Pinter A, Bieber T.
    Adv Ther; 2023 Aug 01; 40(8):3574-3587. PubMed ID: 37332021
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.